Resources
10 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 5/19/2021 (updated 4/10/2024)
CA Bridge, a program of the Public Health Institute, works to ensure that all people with substance use
disorder receive 24/7 access to high-quality care in every California health system. Addiction treatment
should be part of standard medical practice in the emergency department and inpatient settings in order
to increase treatment access and save lives.
Posted 2/18/2021 (updated 4/4/2024)
Opioid use disorder (OUD), a chronic disease, is a major public health problem. Despite availability of effective treatment, too few people receive it and treatment retention is low. Understanding barriers and facilitators of treatment access and retention is needed to improve outcomes for people with OUD.
In this study we sought to assess 3-month outcomes from a patient-centered practice that included MAT with buprenorphine or naltrexone plus the option to participate in psychosocial treatments. The psychosocial treatments included case management, psychotherapy, peer recovery groups such as Narcotics Anonymous or Smart Recovery, or peer support through a local harm reduction program.
Posted 12/16/2020 (updated 4/4/2024)
The curriculum focuses on the effects of substance abuse on families, parenting, and the parent-child relationship, incorporating Joan and Eric Erickson’s eight themes of growth spanning the life cycle and the Stone Center’s Self-in-Relation theory of women’s development. Combining experiential and didactic exercises, this approach is designed to enhance parents’ self-awareness and thereby increase understanding of their children.
Posted 11/9/2021 (updated 4/3/2024)
This workshop will explore the link between Adverse Childhood Experiences (ACEs) of individuals with substance use concerns and its impact on their development. We will explore the experiences, perceptions, beliefs, and behaviors that may present challenges in development. We will discuss practical, trauma-informed, outcome-driven strategies that improve the outcomes.
Posted 7/28/2021 (updated 4/2/2024)
The most effective treatments for opioid use disorder (OUD) are the three prescription medications approved by the U.S. Food and Drug Administration (FDA)—methadone, buprenorphine, and naltrexone—that are proved to increase a patient’s treatment retention and reduce illicit use and the risk of overdose. The only facilities legally able to offer all three medications are opioid treatment programs (OTPs), a critical component of the U.S. substance use treatment system that are regulated by the federal Drug Enforcement Administration (DEA) and Substance Abuse and Mental Health Services Administration (SAMHSA), as well as state agencies, and are certified to administer any FDA-approved medication for the treatment of OUD.
Posted 7/28/2021 (updated 4/2/2024)
This handbook is intended to address this particular set of workplace issues- namely those that arise from experiences of loss, grief and trauma. These issues can surface within the workplace itself, or can be imported into the work setting from workers’ personal lives. This handbook will be useful for managers, supervisors and human resource specialists who are interested in developing their understanding of how the very real issues associated with loss, grief and trauma can be tackled when they show up in work settings. This handbook is a blend of theory and practice, and can be used as a resource for building effective policies and practical responses to the complexities of managing grief, loss and bereavement in the workplace.
Posted 7/16/2020 (updated 3/28/2024)
The information in this document was guided by the vision of the U.S. Department of Health and Human Services’ Office on Women’s Health and lessons learned from a 3-year reentry enhancement project conducted across 3 different reentry organizations. The participating pilot sites were the Resonance Center for Women, Inc., the College and Community Fellowship, and the Institute for Health and Recovery . Using the information compiled through this project, this guide was created by the Substance Abuse and Mental Health Services Administration’s GAINS Center for Behavioral Health and Justice Transformation.
Posted 12/21/2022 (updated 3/27/2024)
The Substance Abuse and Mental Health Services Administration released a notice of proposed rulemaking that would allow certified opioid treatment programs to begin prescribing the drug via audio-only or video-enabled telehealth. See additional information under Policy Updates below. The proposed changes come on top of recent findings by HHS of the positive impact of its revised Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder that removed two longstanding requirements for obtaining a waiver to treat up to 30 patients with buprenorphine: 1) the requirement for specific training, and 2) the need for otherwise eligible clinicians to certify their ability to provide or refer patients for counseling and other services. Rural primary care providers have obtained the DEA waiver at a lower rate than urban clinicians; decreased burden and greater flexibility in the guidelines, along with broader use of telehealth could help close that gap.
Posted 7/27/2022 (updated 3/27/2024)
This presentation will focus on the relationship between trauma and substance use as it relates to treatment for women, as well as a discussion of impactful trauma-informed and gender-responsive interventions. The evidence-based interventions will be based on Seeking Safety and Finding Your Best Self models, both of which are present-focused and easily implemented in any treatment setting.
Posted 3/22/2022 (updated 3/27/2024)
The purpose of this document is to provide detailed guidelines of the Nurse Care Manager Model of Office Based Addiction Treatment program for management of substance use disorders, with particular emphasis on treatment of opioid use disorder with buprenorphine (alone and in combination with naloxone) and naltrexone (oral and extended-release injectable formulations).